50th ASH Annual Meeting and Exposition (December 6 - 9, 2008): Chronic Myeloid Leukemia

Monday, December 8, 2008: 1:30 PM-3:00 PM

2009-2011-2022-2024 - West (Moscone Center)

Moderators:

Mary M. Horowitz, MD, MS and Michele Baccarani

1:30 PM

Significance of Rising Levels of Minimal Residual Disease in Patients with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia (Ph+ CML) in Complete Cytogenetic Response (CGCR)

Hagop M Kantarjian¹, Jianqin Shan²^*, Dan Jones², Susan O'Brien²^*, Mary Beth Rios², Elias Jabbour²^* and Jorge Cortes²^*

¹The University of Texas M. D. Anderson Cancer Center, Houston, TX
²M.D. Anderson Cancer Center, Houston, TX

1:45 PM

446

Efficacy of Nilotinib (formerly AMN107) in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP)

Jorge Cortes¹, Susan O'Brien², Dan Jones²^*, Alessandra Ferrajoli²^*, Marina Konopleva²^*, Gautam Borthakur²^*, Guillermo Garcia-Manero²^*, Laurie A. Letvak³ and Hagop Kantarjian²^*

¹M.D. Anderson Cancer Center, Houston, TX
²The University of Texas M.D. Anderson Cancer Center, Houston, TX
³Novartis Oncology, East Hanover, NJ

2:00 PM

447

Imatinib (IM) Pharmacokinetic (PK) Exposure and Its Correlation with Clinical Outcome in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) for 400 Mg and 800 Mg Daily Doses (Tyrosine Kinase Dose Optimization Study [TOPS])

François Guilhot, MD¹, Timothy P Hughes, MD²^*, Jorge Cortes, MD³, Yanfeng Wang, PhD⁴^*, Michael Hayes, PhD⁴^*, Anthony Gichangi, PhD⁵^*, Brian J. Druker, MD⁶ and Michele Baccarani, MD⁷^*

¹Clinical Investigational Centre INSERM 802, CHU de Poitiers, Poitiers, France
²Haematology, Institute of Medical and Veterinary Science, Adelaide, Australia
³M.D. Anderson Cancer Center, Houston, TX
⁴Novartis Pharmaceuticals, East Hanover, NJ
⁵Novartis Pharmaceuticals, Basel, Switzerland
⁶Oregon Health & Science University Cancer Institute, Portland, OR
⁷Dept. Hematology and Medical Oncology, University of Bologna, Bologna, Italy

2:15 PM

448

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in the Imatinib-Era: High Survival Rate Following Allogeneic HSCT after Imatinib Failure: Results of the German CML Study IV

Susanne Saussele, MD¹^*, Michael Lauseker²^*, Alois Gratwohl, MD³, Dominik Heim, MD³^*, Dietrich Wilhelm Beelen, MD⁴^*, Hartmut Döhner, MD⁵, Rainer Schwerdtfeger, MD⁶, Anthony D. Ho, MD⁷^*, Hans-Jochem Kolb, MD⁸^*, Markus Pfirrmann, PhD²^*, Martin C. Müller, MD¹^*, Armin Leitner, MD¹^*, Ulrike Proetel, MD¹^*, Elena Kovalevskaya, MD¹^*, Claudia Haferlach, MD⁹^*, Brigitte Schlegelberger, MD¹⁰, Joerg Hasford, MD²^*, Andreas Hochhaus, MD¹ and Ruediger Hehlmann, MD¹

¹Medical Faculty Mannheim, University Heidelberg, Mannheim, Germany
²IBE University, München, Germany
³University Hospital, Basel, Switzerland
⁴BMT Unit, University, Essen, Germany
⁵University, Ulm, Germany
⁶German Diagnostic Clinic, Wiesbaden, Germany
⁷Medical Faculty, University, Heidelberg, Germany
⁸Department of Medicine, University, München
⁹MLL Leukemia Laboratory, München, Germany
¹⁰Inst. of Cell & Molecular Pathology, MHH, Hannover, Germany

2:30 PM

449

Dasatinib Efficacy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Pre-Existing BCR-ABL Mutations

Martin C Müller¹^*, Jorge Cortes, MD², Dong-Wook Kim, MD, PhD³^*, Brian J. Druker⁴, Philipp Erben, MD¹^*, Ricardo Pasquini⁵^*, Timothy P Hughes, MD⁶^*, Yousif Matloub⁷^*, Lynn Ploughman⁷^* and Andreas Hochhaus, MD¹

¹Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany
²M.D. Anderson Cancer Center, Houston, TX
³Division of Hematology, St. Mary's Hospital, Seoul, South Korea
⁴Oregon Health & Science University Cancer Institute, Portland, OR
⁵Universidade Federal do Paraná, Curitiba, Brazil
⁶Haematology, Institute of Medical and Veterinary Science, Adelaide, Australia
⁷Bristol-Myers Squibb, Wallingford, CT

2:45 PM

450

Dasatinib Time to and Durability of Major and Complete Cytogenetic Response (MCyR and CCyR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Michele Baccarani, MD¹, Gianantonio Rosti¹^*, Giuseppe Saglio, MD²^*, Jorge Cortes³^*, Richard Stone⁴^*, Dietger W. Niederwieser, MD⁵, Eric Bleickardt⁶^*, Ritwik Sinha⁶^* and Bengt Simonsson⁷

¹'L. and A. Seragnoli', Istituto di Ematologia e, Bologna, Italy
²Department of Clinical and Biological Sciences, University of Turin, Orbassano,Turin, Italy
³The University of Texas MD Anderson Cancer Center, Houston, TX
⁴Dana Farber Cancer Institute, Boston, MA
⁵Abteilung Hamatologie/Onkologie, Universitat Leipzig, Leipzig, Germany
⁶Bristol-Myers Squibb, Wallingford, CT
⁷Department of Hematology, University Hospital, Uppsala, Sweden

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

632.O3.6 Chronic Myeloid Leukemia - Clinical Trials II